Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

0.60USD
28 Apr 2017
Change (% chg)

$0.00 (+0.25%)
Prev Close
$0.60
Open
$0.61
Day's High
$0.61
Day's Low
$0.60
Volume
21,008
Avg. Vol
68,307
52-wk High
$1.14
52-wk Low
$0.50

AVEO.OQ

Chart for AVEO.OQ

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $66.55
Shares Outstanding(Mil.): 110.36
Dividend: --
Yield (%): --

Financials

  AVEO.OQ Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -0.40 -- --
ROI: -119.29 -0.42 13.25
ROE: -351.37 5.87 14.41

BRIEF-Aveo announces submission of response to Tivozanib marketing authorization application day 180 list of outstanding issues

* Aveo announces submission of response to tivozanib marketing authorization application day 180 list of outstanding issues

Apr 13 2017

BRIEF-Aveo announces pricing of $15 mln public offering of common stock

* Aveo announces pricing of $15.0 million public offering of common stock

Mar 28 2017

BRIEF-Aveo announces proposed offering of common stock

* Aveo Pharmaceuticals- offering's proceeds to be used in development, pre-commercial expenses incurred for ongoing phase 3 clinical trial of tivozanib Source text for Eikon: Further company coverage:

Mar 28 2017

BRIEF-Aveo Pharmaceuticals says doubts ability to continue as a going concern - SEC filing

* Aveo Pharmaceuticals says have identified conditions and events that raise substantial doubt about ability to continue as a going concern - SEC filing

Mar 22 2017

BRIEF-Aveo reports full year 2016 financial results

* Aveo reports full year 2016 financial results and provides business update

Mar 22 2017

BRIEF-Aveo announces first patient dosed in phase 1/2 tinivo trial

* Aveo announces first patient dosed in phase 1/2 tinivo trial of tivozanib and opdivo (nivolumab) in advanced RCC

Mar 22 2017

BRIEF-Aveo Pharmaceuticals files for non-timely 10-K - SEC filing

* Says identified a material weakness in its internal control over financial reporting.

Mar 17 2017

BRIEF-Aveo reports clinical and regulatory updates for tivozanib

* Aveo announces clinical and regulatory updates for tivozanib

Feb 09 2017

BRIEF-Aveo Pharmaceuticals says Eusa Pharma submits its responses to EMA day 120 list of questions

* Says its development partner, Eusa Pharma, submitted its responses to European Medicines Agency (EMA) day 120 list of questions

Nov 28 2016

BRIEF-Aveo Oncology Q3 loss per share $0.07

* Says believe that $30.8 million in cash resources could allow to fund planned operations into Q4 of 2017

Nov 04 2016

More From Around the Web

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,464 -9.50
Eisai Co., Ltd (4523.T) ¥5,823 -29.00
Pfizer Inc. (PFE.N) $33.92 +0.06
Novartis AG (NOVN.S) CHF76.55 -0.35
Roche Holding Ltd. (ROG.S) CHF260.30 0.00
Roche Holding Ltd. (RO.S) CHF260.50 -1.00
Bayer AG (BAYGn.DE) €113.60 +0.95
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €86.61 +0.64
AstraZeneca plc (AZN.L) 4,637.50 -60.50

Earnings vs. Estimates